(PharmaNewsWire.Com, July 03, 2019 ) According to the latest report by IMARC Group, titled “Global H1N1 Vaccines Market and Forecast 2019-2024”, the global H1N1 vaccines market is currently exhibiting strong growth. H1N1 influenza is an extremely infectious respiratory disease caused by influenza viruses commonly found in pigs. Also known as swine flu or pig flu, it is transmitted through the saliva of the infected person that gets expelled into the air while coughing or sneezing. The symptoms may include high fever, persistent cough, reduced appetite, nasal secretions, body ache, red-watery eyes and headaches. Over the past few years, the flu has resulted in several deaths across the globe. As a result, H1N1 vaccination is being widely adopted as a preventive measure that aids the body to fight against the disease. The vaccine contains a small dose of the virus that is injected in the body and builds immunity against the same.
The increasing number of swine flu cases and deteriorating immunity of the majority of the population have bolstered the sales of H1N1 vaccines worldwide. This can be accredited to sedentary lifestyles, hectic schedules and decreasing intake of healthy food items, especially among the working population. Moreover, significant growth in the geriatric population also acts as a major growth-inducing factor. Since the geriatric population is more likely to develop respiratory tract diseases and immunodeficiency disorders, the risk of acquiring swine flu infection is higher for this population group. Apart from this, initiatives taken by several national and international organizations worldwide are also positively impacting the growth of the market. For instance, the World Health Organization (WHO) is constantly investing in the development of competent vaccines and their effective distribution.
On the basis of vaccine type, the market has been divided into intramuscular, intranasal and intradermal. Amongst these, intramuscular represents the most preferred vaccine type.
On the basis of the market type, the market has been bifurcated into public and private segments. At present, the public segment accounts for the majority of the total market share.
Based on the key brand, the market has been categorized into Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip and others.
On the geographical front, North America holds the leading position in the market. Other major regions include Europe, Asia Pacific, Middle East and Africa, and Latin America.
The competitive landscape of the market has also been studied with the detailed profiles of the key players operating in the market.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
